CEVR analyzes the benefits, risks, and costs of strategies to improve health and health care.

About Us
Data

News & Events

Recent Publications

Valuing and pricing Remdesivir: Should drug makers get paid for helping us get back to work?

Health Affairs Blog

Cohen JT, Neumann PJ, Ollendorf DA. "Valuing and pricing Remdesivir: Should drug makers get paid for helping us get back to work?," Health Affairs Blog, May 20, 2020.

Analyzing the cost effectiveness of policy responses for COVID-19: The importance of capturing social consequences

Medical Decision Making Research Letter

Kim DD, Neumann PJ. "Analyzing the cost effectiveness of policy responses for COVID-19: The importance of capturing social consequences," Medical Decision Making Research Letter, May 19, 2020.

Coverage for Biosimilars vs reference products among US commercial health plans

Journal of the American Medical Association

Chambers JD, Lai RC, Margaretos NM, Panzer AD, Cohen JT, Neumann PJ. "Coverage for Biosimilars vs reference products among US commercial health plans," Journal of the American Medical Association Research Letter, May 19, 2020.

Growth and capacity for cost‐effectiveness analysis in Africa

Health Economics

Panzer AD, Emerson JG, D'Cruz B, Patel A, Dabak S, Isaranuwatchai W, Kim DD. "Growth and capacity for cost‐effectiveness analysis in Africa," Health Economics Letter, May 15, 2020.

Balancing value with affordability: Cell immunotherapy for cancer treatment in the U.S.

The Oncologist

Leech AA, Neumann PJ, Cohen JT, Jagasia M, Dusetzina SB. Balancing value with affordability: Cell immunotherapy for cancer treatment in the U.S. The Oncologist 2020.

Two-year outcomes and cost for heart failure patients following discharge from the hospital after an acute heart failure admission

International Journal of Cardiology

Olchanski N, Vest AR, Cohen JT, Denofrio D. Two-year outcomes and cost for heart failure patients following discharge from the hospital after an acute heart failure admission. International Journal of Cardiology 2020;307:109–13.

Using QALYs versus DALYs to measure cost-effectiveness: How much does it matter?

International Journal of Technology Assessment in Health Care

Feng X, Kim DD, Cohen JT, Neumann PJ, Ollendorf DA. Using QALYs versus DALYs to measure cost-effectiveness: How much does it matter? International Journal of Technology Assessment in Health Care 2020;:1–8.

What types of real-world evidence studies do U.S. commercial health plans cite in their specialty drug coverage decisions?

Pharmacoepidemiology and Drug Safety

Panzer AD, Margaretos NM, Lai RC, Enright DE, Chambers JD. What types of real-world evidence studies do U.S. commercial health plans cite in their specialty drug coverage decisions? Pharmacoepidemiology and Drug Safety 2020;1–5.

Racial and ethnic differences in knowledge about one's dementia status

Journal of the American Geriatrics Society

Lin PJ, Emerson J, Faul JD, Cohen JT,  Neumann PJ, Fillit HM, Daly AT, Margaretos N, Freund KM. Racial and ethnic differences in knowledge about one's dementia status. Journal of the American Geriatrics Society (in press).

Orphan drugs offer larger health gains but less favorable cost-effectiveness than non-orphan drugs

Journal of General Internal Medicine

Chambers JD, Silver MC, Berklein FC, Cohen JT, Neumann PJ. Orphan Drugs Offer Larger Health Gains but Less Favorable Cost-effectiveness than Non-orphan Drugs. Journal of General Internal Medicine 2020.

The supercar stays in the garage: Factors preventing indirect comparisons of novel medicines targeting the same condition

Journal of Managed Care & Specialty Pharmacy

Ollendorf DA, Kim E, Bridger N, Naci H. The supercar stays in the garage: Factors preventing indirect comparisons of novel medicines targeting the same condition. Journal of Managed Care & Specialty Pharmacy 2020;26(3):333–4.

Comparing inpatient costs of heart failure admissions for patients with reduced and preserved ejection fraction with or without type 2 diabetes

Cardiovascular Endocrinology & Metabolism

Olchanski N, Amanda VR, Cohen JT, DeNofrio D. Comparing inpatient costs of heart failure admissions for patients with reduced and preserved ejection fraction with or without type 2 diabetes. Cardiovascular Endocrinology & Metabolism 2020;9(1):17–23.

Are low and middle-income countries prioritising high-value healthcare interventions?

BMJ Global Health

Leech AA, Kim DD, Cohen JT, Neumann PJ. Are low and middle-income countries prioritising high-value healthcare interventions? BMJ Global Health 2020;5(2).

Prevention of non-communicable disease: Best buys, wasted buys, and contestable buys

BMJ

Isaranuwatchai W, Teerawattananon Y, Archer RA, Luz A, Sharma M, Rattanavipapong W, Anothaisintawee T, Bacon RL, Bhatia T, Bump J, Chalkidou K, Elshaug AG, Kim DD, Reddiar SK, Nakamura R, Neumann PJ, Shichijo A, Smith PC, Culyer AJ. Prevention of non-communicable disease: Best buys, wasted buys, and contestable buys. BMJ 2020.

Hospital care at home: Better, cheaper, faster?

Annals of Internal Medicine

Wong JB, Cohen JT. "Hospital care at home: Better, cheaper, faster?," Annals of Internal Medicine Editorial, January 21, 2020.

The CEVR Team

Our team of experienced, dedicated researchers is led by health economists Peter Neumann and Josh Cohen. Together we produce cutting-edge health care cost-effectiveness research.

Meet the CEVR Team

Our Databases

Our comprehensive databases provide the information individuals and organizations need to analyze the benefits, risks, and costs of strategies to improve health and health care.